Advertisement

Vitamin E in extrapyramidal disorders

  • L. Bischot
  • G. Van den Brink
  • A. J. Porsius
Editorial

Abstract

In this article the effect of vitamin E on two extrapyramidal disorders, tardive dyskinesia and Parkinson's disease, is reviewed. After a brief description of the symptoms, the current hypotheses for the pathogenesis of these diseases are described. A summary of the clinical research that has been done to establish the effectiveness of vitamin E is given. In tardive dyskinesia four clinical trials (double-blind, placebo-controlled) showed improvement in the symptoms with vitamin E in doses of up to 1,600 IU/day. Preliminary studies concerning Parkinson's disease suggested that vitamin E (2,000 IU/day) probably cannot prevent the development of the disease. It was suggested that vitamin E is able to slow the progression of the illness. The results from a large double-blind, placebocontrolled clinical trial, however, did not show any beneficial effect of vitamin E in Parkinson's disease.

Keywords

Antioxidants Clinical trials Dyskinesia, drug-induced Free radicals Parkinson disease Pathology Vitamin E 

References

  1. 1.
    Kleijnen J, Knipschild P, Ter Riet G. Vitamin E and cardiovascular disease. Eur J Clin Pharmacol 1989;37:541–4.PubMedGoogle Scholar
  2. 2.
    Ehrenkranz RA. Vitamin E and the neonate. Am J Dis Child 1980;34:1157–66.Google Scholar
  3. 3.
    Willson RL Free radical protection: why vitamin E, not vitamin C, betacarotene or glutathione? CIBA Found Symp 1983;101:19–44.PubMedGoogle Scholar
  4. 4.
    Nagaoka S, Kuranaka A, Tsuboi H, Nagashima U, Mukai K. Mechanism of the antioxidant reaction of vitamin E. Charge-transfer and tunnelling effect in proton transfer reaction. J Phys Chem 1992;96:2754–61.CrossRefGoogle Scholar
  5. 5.
    Jeste DV, Krull AJ, Kilbourn K. Tardive dyskinesia — managing a common neuroleptic side effect. Geriatrics 1990;45:49–58.PubMedGoogle Scholar
  6. 6.
    Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic induced movement disorders — evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 1989;570:176–85.PubMedCrossRefGoogle Scholar
  7. 7.
    Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia. Arch Gen Psychiatry 1982;39:803–14.PubMedGoogle Scholar
  8. 8.
    Lohr JB, Cadet JL, Lohr MA, Larson L, Wasli E, Wade L, et al. Vitamin E in treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 1988;14:291–6.PubMedGoogle Scholar
  9. 9.
    Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107–8.CrossRefGoogle Scholar
  10. 10.
    Junker D, Steigleider P, Gattaz WF. Alpha-tocopherol in the treatment of tardive dyskinesia. Schizophr Res 1992;6:122–3.CrossRefGoogle Scholar
  11. 11.
    Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990;28:535–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Elkashef AM, Ruskin PE, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 1990;147:505–6.PubMedGoogle Scholar
  13. 13.
    Egan MF, Hyde TM, Alberts GW, Elkashef A, Alexander RC, Reeve A, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992;149:773–7.PubMedGoogle Scholar
  14. 14.
    Shriqui CL, Bradwejn J, Annable L, Jones BD. Vitamin E in the treatment of tardive dyskinesia. A double blind placebocontrolled study. Am J Psychiatry 1992;149:391–3.PubMedGoogle Scholar
  15. 15.
    Porsius AJ. Vrij radicale therapieën voor een motorisch gestoorde patiënt (I). [Rather radical therapies in a patient with motor disturbances]. Pharm Weekbl 1992;127:869–72.Google Scholar
  16. 16.
    Fahn S. An open trial of high dosage antioxidants in early Parkinson's disease. Am J Clin Nutr 1991;53:380S-2S.PubMedGoogle Scholar
  17. 17.
    Tanner CM. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci 1989;12:49–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Fahn S. The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high dosage antioxidants in an attempt to slow the progression of the illness. Ann N Y Acad Sci 1989;570:186–96.PubMedCrossRefGoogle Scholar
  19. 19.
    Shoulson I, Parkinson Study Group. Deprenyl and tocopherol antioxidant therapy of parkinsonism (DATATOP). Acta Neurol Scand 1989;126:171–5.CrossRefGoogle Scholar
  20. 20.
    Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32–7.PubMedGoogle Scholar
  21. 21.
    Lohr JB. Oxygen radicals and neuropsychiatrie illness. Arch Gen Psychiatry 1991;48:1096–106.Google Scholar
  22. 22.
    Grimes JD, Hassan MN, Thakar JH. Prevention of progression in Parkinson's disease with antioxidant therapy. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:165–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Jansen ENH, Neef C. Neuroprotectie door selegiline. [Neuroprotection by selegiline]. Pharm Weekbl 1992;127:571–5.Google Scholar
  24. 24.
    Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052–60.Google Scholar
  25. 25.
    Gotz ME, Freyberger A, Riederer P. Oxidative stress: a role in the pathogenesis of Parkinson's disease. J Neural Transm 1990;29:241S-9S.Google Scholar
  26. 26.
    Grimes JD, Hassan MN, Thakar JH. Antioxidant therapy in Parkinson's disease. Can J Neurol Sci 1987;14:483–7.PubMedGoogle Scholar
  27. 27.
    Collier DS, Berg MJ, Fincham RW. Parkinsonism treatment part III update. Ann Pharmacother 1992;26:227–33.PubMedGoogle Scholar
  28. 28.
    Snyder SH, D'Amato RJ. MPTP a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 1986;36:250–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Koller W, Vetere-Overfield B, Gray C, Alexander C, Chin T, Dolezal J, et al. Environmental risk factors in Parkinson's disease. Neurology 1990;40:1218–21.PubMedGoogle Scholar
  30. 30.
    Tanner CM, Langston JW. Do environmental toxins cause Parkinson's disease? Neurology 1990;40:17–30.PubMedGoogle Scholar
  31. 31.
    Marsden CD. Parkinson's disease. Lancet 1990;1:948–52.CrossRefGoogle Scholar
  32. 32.
    Factor SA, Weiner WJ. Retrospective evaluation of vitamin E therapy in Parkinson's disease. Ann N Y Acad Sci 1989;570:441–2.CrossRefGoogle Scholar
  33. 33.
    Factor SA, Sanchez-Ramos JR, Weiner WJ. Vitamin E therapy in Parkinson's disease. Acta Neurol 1990;53:457–61.Google Scholar
  34. 34.
    Wolters ECH, Kuiper MA, Horstink MWIM. Selegiline bij de ziekte van Parkinson; symptomatisch of causaal effect? [Selegiline in Parkinson's disease; symptomatic or causal effect?] Ned Tijdschr Geneeskd 1992;136:1544–7.PubMedGoogle Scholar
  35. 35.
    Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176–83.CrossRefGoogle Scholar

Copyright information

© Periodicals Service Company 1993

Authors and Affiliations

  • L. Bischot
    • 1
  • G. Van den Brink
    • 1
  • A. J. Porsius
    • 1
  1. 1.Department of Pharmacotherapy, Faculty of PharmacyUtrecht UniversityTB UtrechtThe Netherlands

Personalised recommendations